Title of article :
Prospective, randomized evaluation of thrombectomy prior to percutaneous intervention in diseased saphenous vein grafts and thrombus-containing coronary arteries
Author/Authors :
Gregg W. Stone، نويسنده , , David A. Cox، نويسنده , , Joseph Babb، نويسنده , , Dean Nukta، نويسنده , , Luc Bilodeau، نويسنده , , Louis Cannon، نويسنده , , Thomas D. Stuckey، نويسنده , , James Hermiller، نويسنده , , Eric A. Cohen، نويسنده , , Reginald Low، نويسنده , , Steven R. Bailey، نويسنده , , Alexandra J. Lansky، نويسنده , , Richard E. Kuntz and for the X-TRACT Investigators، نويسنده ,
Issue Information :
روزنامه با شماره پیاپی سال 2003
Pages :
7
From page :
2007
To page :
2013
Abstract :
Objectives We sought to determine whether routine thrombectomy prior to stent implantation in diseased saphenous vein grafts (SVGs) and thrombus-containing native coronary arteries would reduce peri-procedural myonecrosis and subsequently enhance event-free survival. Background Percutaneous coronary intervention in diseased SVGs and thrombotic native coronary arteries is complicated by a high rate of peri-procedural myocardial infarction (MI). Thrombectomy prior to intervention may enhance the safety of intervention and improve early and late outcomes in these high-risk patients. Methods At 60 centers in the U.S. and Canada, 797 patients with 839 diseased SVGs or thrombus-containing native coronary arteries were prospectively randomized to stent implantation with versus without prior thrombectomy with the X-SIZER device (ev3, Plymouth, Minnesota). Results Peri-procedural MI occurred in 15.8% of patients assigned to the X-SIZER device compared with 16.6% of control patients (p = 0.77), although the rate of large MI (pre-specified as the development of new pathologic Q waves or creatine phosphokinase-MB isoenzyme elevation >8 × upper limits of normal) was reduced with X-SIZER device use from 9.6% to 5.5% (multivariate risk ratio 0.35 [95% confidence interval 0.18 to 0.66], p = 0.002). Major adverse cardiac events (cardiac death, MI, or repeat target vessel revascularization) occurred in 16.8% of X-SIZER patients versus 17.1% of control patients at 30 days (p = 0.92), and in 31.3% of X-SIZER patients versus 28.2% of control patients at 1 year (p = 0.35). Conclusions Thrombectomy with the X-SIZER device prior to stent implantation in high-risk diseased SVGs and thrombus-containing native coronary arteries may reduce the extent, but not the occurrence, of myonecrosis. Early and late event-free survival, however, were not improved by routine thrombectomy with this device.
Keywords :
Thrombolysis In Myocardial Infarction , TVR , CPK , ULN , target vessel revascularization , creatine phosphokinase , upper limit of normal , GP , X-TRACT , major adverse cardiac events , Glycoprotein , X-SIZER for Treatment of Thrombus and Atherosclerosis in Coronary Interventions Trial , MI , PCI , Percutaneous coronary intervention , SVG , mace , myocardial infarction , TIMI , saphenous vein graft
Journal title :
JACC (Journal of the American College of Cardiology)
Serial Year :
2003
Journal title :
JACC (Journal of the American College of Cardiology)
Record number :
598443
Link To Document :
بازگشت